PL445561A1 - Method for optimizing whole blood lead concentration in women - Google Patents

Method for optimizing whole blood lead concentration in women

Info

Publication number
PL445561A1
PL445561A1 PL445561A PL44556123A PL445561A1 PL 445561 A1 PL445561 A1 PL 445561A1 PL 445561 A PL445561 A PL 445561A PL 44556123 A PL44556123 A PL 44556123A PL 445561 A1 PL445561 A1 PL 445561A1
Authority
PL
Poland
Prior art keywords
women
blood lead
whole blood
lead concentration
optimizing whole
Prior art date
Application number
PL445561A
Other languages
Polish (pl)
Inventor
Jan LUBIŃSKI
Ewa Siwiec
Róża Derkacz
Wojciech MARCINIAK
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL445561A priority Critical patent/PL445561A1/en
Publication of PL445561A1 publication Critical patent/PL445561A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób obniżania niskich (<20 µg/l) stężeń ołowiu we krwi, polega on na tym, że obejmuje suplementację DMSA w dawce 10 mg/kg masy ciała/dzień co skutkuje obniżeniem o ponad 50% poziomu ołowiu we krwi u kobiet już po 4 tygodniach.The subject of the application is a method of reducing low (<20 µg/l) blood lead concentrations, which involves supplementation with DMSA at a dose of 10 mg/kg body weight/day, which results in a reduction of blood lead levels in women by more than 50% after just 4 weeks.

PL445561A 2023-07-12 2023-07-12 Method for optimizing whole blood lead concentration in women PL445561A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL445561A PL445561A1 (en) 2023-07-12 2023-07-12 Method for optimizing whole blood lead concentration in women

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL445561A PL445561A1 (en) 2023-07-12 2023-07-12 Method for optimizing whole blood lead concentration in women

Publications (1)

Publication Number Publication Date
PL445561A1 true PL445561A1 (en) 2025-01-13

Family

ID=94177721

Family Applications (1)

Application Number Title Priority Date Filing Date
PL445561A PL445561A1 (en) 2023-07-12 2023-07-12 Method for optimizing whole blood lead concentration in women

Country Status (1)

Country Link
PL (1) PL445561A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041657A1 (en) * 2003-10-20 2005-05-12 Framework Therapeutics, L.L.C. Zeolite molecular sieves for the removal of toxins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041657A1 (en) * 2003-10-20 2005-05-12 Framework Therapeutics, L.L.C. Zeolite molecular sieves for the removal of toxins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRACIA, R.C. ET AL.: "American Journal of Health-System Pharmacy, Volume 64, Issue 1, 1 January 2007, Pages 45–53", „LEAD TOXICITY AND CHELATION THERAPY" *
SAMPLE, J.A.: "9-01-2024, publikacja dostępna pod adresem https://medilib.ir/uptodate/show/6494", „CHILDHOOD LEAD POISONING: MANAGEMENT" *
SHRODER, A.P. ET AL.: "US Pharm. 2015; 40(5):40-44", "LEAD TOXICITY AND CHELATION THERAPY" *

Similar Documents

Publication Publication Date Title
Cory-Slechta et al. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy.
MX2023000589A (en) Combination therapy for treating abnormal cell growth.
AR087378A1 (en) WELL MAINTENANCE FLUID AND METHOD FOR MAINTENANCE OF A WELL WITH THE FLUID
NZ766027A (en) Contraceptive composition with reduced cardiovascular effects
Drewnoski et al. Ferric citrate decreases ruminal hydrogen sulphide concentrations in feedlot cattle fed diets high in sulphate
Frassetto et al. How metabolic acidosis and oxidative stress alone and interacting may increase the risk of fracture in diabetic subjects
MX2024011403A (en) Mirdametinib treatment.
Ognik et al. The effect of a probiotic containing Enterococcus faecium DSM 7134 on redox and biochemical parameters in chicken blood
PL445561A1 (en) Method for optimizing whole blood lead concentration in women
PH12022550753A1 (en) A mesenchymal stem cell storing or transport formulation and methods of making and using the same
TW200735863A (en) Dietary compositions for enhancing metabolism and reducing reactive oxygen species
PH12021553055A1 (en) Methods and compositions for improving outcomes of cancer patients
BR112021022208A2 (en) Methods for treating muscular dystrophy using inhibitor oligonucleotides for cd49d
CO5611129A2 (en) CO-THERAPY WITH OXAZOLIDINONA
Ibrahim et al. Effect of selenium and zinc supplementation on hypothyroidism in rats
Jelodar et al. Arginase alteration in the reproductive system of alloxan-diabetic dogs
PH12020551330A1 (en) Insecticidal composition and use thereof
WO2024073420A3 (en) Administration of glutathione trisulfide to ameliorate peripheral neuropathy
Gaulden et al. Micronutrients in congestive heart failure: an integrative review
MX2022001281A (en) Electrolyte composition and methods of use.
Kawata et al. Breeding severely vitamin B12-deficient mice as model animals
UA158367U (en) A method for obtaining a composition for the treatment of the nose in the form of an ointment
Hulter et al. Chronic hyperkalemic renal tubular acidosis induced by KCl loading
PL427987A1 (en) Method for modifying arsenic concentration
PL439274A1 (en) Method of modifying arsenic concentration in the blood with vitamin C supplementation